Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for AIM ImmunoTech Inc. (AIM : AMEX)

• Company Description    AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases. The company's flagship products include Ampligen(R), Rintamod(R) and Alferon N Injection(R) which are in clinical stage. AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is based in Ocala, Florida. Number of Employees: 23

• Price / Volume Information    Yesterday's Closing Price: $9.36 Daily Weekly Monthly 20 Day Moving Average: 15,100 shares Shares Outstanding: 0.76 (millions) Market Capitalization: $7.15 (millions) Beta: 0.98 52 Week High: $10.38 52 Week Low: $0.03 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 11.65% 7.47% 12 Week 167.33% 124.86% Year To Date -52.74% -55.75%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2117 SW HIGHWAY 484 - OCALA,FL 34473 USA ph: 352-448-7797 fax: 215-988-1739 aim@jtcir.com http://www.aimimmuno.com

• General Corporate Information    Officers Thomas K. Equels - Chief Executive Officer & President William Mitchell - Chairman of the Board Peter Rodino - Chief Operating Officer; General Counsel & Secreta Robert Dickey - Chief Financial Officer Ted D. Kellner - Director Peer Information AIM ImmunoTech Inc. (GSAC) AIM ImmunoTech Inc. (CASI) AIM ImmunoTech Inc. (ALCD.) AIM ImmunoTech Inc. (OMNN) AIM ImmunoTech Inc. (CGPI.) AIM ImmunoTech Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 00901B303 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/13/25 Share - Related Items Shares Outstanding: 0.76 Most Recent Split Date: 6.00 (0.01:1) Beta: 0.98 Market Capitalization: $7.15 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-8.00 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-31.00 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 48.98 EPS Growth vs. Year Ago Period: 58.33% vs. Previous Quarter: 50.00% Sales Growth vs. Year Ago Period: -60.00% vs. Previous Quarter: -64.44% ROE 06/30/25 - - 03/31/25 - -1,586.23 12/31/24 - -585.68 ROA 06/30/25 - - 03/31/25 - -137.76 12/31/24 - -128.06 Current Ratio 06/30/25 - - 03/31/25 - 0.26 12/31/24 - 0.44 Quick Ratio 06/30/25 - - 03/31/25 - 0.26 12/31/24 - 0.44 Operating Margin 06/30/25 - - 03/31/25 - -10,416.44 12/31/24 - -10,188.23 Net Margin 06/30/25 - - 03/31/25 - -10,416.44 12/31/24 - -10,188.23 Pre-Tax Margin 06/30/25 - - 03/31/25 - -10,416.44 12/31/24 - -10,188.23 Book Value 06/30/25 - - 03/31/25 - -5.34 12/31/24 - -2.07 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©